Fenoterol

The control of acute exacerbations of airway obstructive diseases such as bronchial asthma and chronic obstructive pulmonary disease (COPD) has always been a key clinical demand in the respiratory field. The emergence of highly selective β₂ adrenoceptor agonists provides a core solution for rapid antispasmodic treatment of these diseases. As a second-generation highly selective β₂ receptor agonist, fenoterol can relax bronchial smooth muscle and inhibit the release of inflammatory mediators by activating β₂ receptors on the surface of airway smooth muscle. Meanwhile, it has minimal impact on cardiac β₁ receptors, and the incidence of cardiac adverse reactions is much lower than that of first-generation non-selective β receptor agonists. Clinically, it is mainly used for the palliative treatment of acute exacerbations of bronchial asthma, asthmatic bronchitis, and COPD with bronchospasm, and the applicable population covers adults and pediatric patients over 5 years old.

The global market size of fenoterol preparations is stably around 320 million US dollars, with an annual compound growth rate of approximately 2.8%. The growth momentum mainly comes from the improvement of asthma prevention and control coverage in low- and middle-income countries. At present, the domestic market is dominated by imported original research preparations, the number of applications for domestic generic preparations is small, and the raw material drug supply side has not yet formed a fully competitive pattern. With the continuous release of demand for chronic disease management medication in the respiratory field, the clinical usage of fenoterol still has an upward space of 15% to 20%.

The original research enterprise of fenoterol is Boehringer Ingelheim of Germany, and the original research brand name is Berotec. Its core compound patent expired globally in 1986. The mainstream dosage form of the original research is fenoterol hydrobromide solution for inhalation, with the specification of 20ml:0.1g, which has been included in the FDA Reference Listed Drug Catalog and China's *Catalog of Reference Preparations for Chemical Drugs (5th Batch)*. At present, there is no publicly announced domestic A-state registration number for fenoterol active pharmaceutical ingredients in China. Only the original imported preparation was approved for marketing in China in 1996, and no domestic preparation has been approved. (Data as of October 2024, please refer to the official website of CDE for the latest information)

CATO can provide a full set of fenoterol impurity reference standards. Most products are in stock. For in-stock orders placed before 16:00, delivery can be made on the same day. All products meet the requirements of multiple national regulations such as Chinese Pharmacopoeia and FDA, and can fully meet the use needs of various reference standards in the stages of API research and development, quality research and registration application.